Trial Profile

A clinical study to evaluate TAGRISSO® (osimertinib) in combination with IK-930 as treatment for patients with EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 30 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 May 2024 According to an Ikena Oncology media release, based on a review of clinical data to date, available resources, and the Company's strategic priorities, the Company decided to discontinue development of IK-930. The IK-930 Phase 1 program will begin winddown activities; treatment will continue for patients enrolled to date who have derived benefit. The Company will seek strategic options for the program, including potential partners for development of IK-930 in combination with other targeted agent
28 May 2024 Status changed from planning to discontinued, according to an Ikena Oncology media release.
28 Nov 2022 According to an Ikena Oncology media release, plan to initiate this trial in first half of 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com